TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: A planned subset analysis of a phase II multicenter study evaluating the use of BV in CD30-positive non-Hodgkin-lymphoma PTCL demonstrated an ORR of 33% in PTCL-NOS patients and an ORR of 54% in AITL patients [53,54].